- Home
- EEA vs GOSS Comparison
EEA vs GOSS Comparison
Compare EEA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EEA | GOSS |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.5M | 70.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EEA | GOSS |
|---|---|---|
| Price | $10.05 | $9.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $95.40 |
| AVG Volume (30 Days) | 31.0K | ★ 262.7K |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.62 | $0.11 |
| 52 Week High | $11.43 | $12.52 |
Technical Indicators
Market Signals| Indicator | EEA | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 33.01 | 55.31 |
| Support Level | $10.03 | $0.18 |
| Resistance Level | $11.14 | $12.49 |
| Average True Range (ATR) | 0.26 | 0.70 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 4.73 | 45.08 |
Price Performance
Historical ComparisonAbout EEA The European Equity Fund Inc.
European Equity Fund, Inc / MD is a United States-based diversified, closed-end management investment company. The fund seeks long-term capital appreciation through investment in equity and equity securities of issuers domiciled in Europe. Its portfolio of investments consists of different sectors such as industrials, financials, healthcare, consumer discretionary, materials, consumer staples, information technology, and other sectors.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).